Y Fujiwara, R Makihara, T Hase, N Hashimoto… - Cancer …, 2023 - Wiley Online Library
The safety of osimertinib is limited in patients with severe or moderate renal impairment, or
low body weight. This study aimed to investigate the safety, pharmacokinetics (PK) and …